(Reuters) -British drugmaker GSK said on Monday its supplemental new drug application for antibiotic drug gepotidacin has been accepted for priority review by the U.S. Food and Drug Administration for the oral treatment of uncomplicated urogenital gonorrhoea.
(Reporting by Yadarisa Shabong in Bengaluru; Editing by Rashmi Aich)
